WHO 发布第 3/2026 号医疗产品警报：马尔代夫和墨西哥发现伪造 DARZALEX（daratumumab）
Medical Product Alert N°3/2026: Falsified DARZALEX (daratumumab)
WHO 发布第 3/2026 号医疗产品警报，涉及在马尔代夫和墨西哥发现的两批伪造 DARZALEX（daratumumab）注射剂。伪造批号 MYS7381 和 STV1K01 已被原厂 JANSSEN 确认无效，马尔代夫食品和药品管理局报告批号 STV1K01 的药瓶中出现可见颗粒物。
材料列明了两个伪造批号、颗粒物发现及未授权经销商供货渠道，便于读者核对供应链环节与假药识别特征。
Alert Summary
This WHO Medical Product Alert concerns two batches of falsified DARZALEX (daratumumab) injection. The falsified products were detected in Maldives and Mexico. National Regulatory Authorities in both countries reported the incidents to WHO in May and June 2026. The falsified products were supplied or offered by non-authorized distributors and, in at least one case, hospitals received these falsified products.
DARZALEX is a medicine (monoclonal antibody) used to treat rare blood disorders and cancers that affect bone marrow, specifically multiple myeloma and amyloid light-chain (AL) amyloidosis.
How to identify these falsified products
These products are considered falsified because they deliberately misrepresent their identity, composition, or source.
The genuine manufacturer, JANSSEN, has confirmed that the batch numbers on the falsified products, MYS7381 and STV1K01, are not valid. Any DARZALEX product with these batch numbers should be considered falsified and not used.
The Maldives Food and Drug Authority reported visible particulate matter in vials of falsified DARZALEX, batch STV1K01.
Risks
Falsified DARZALEX (daratumumab) poses a serious risk to patient safety. No laboratory testing has been conducted on these products. Their contents, quality, and sterility remain unknown. They may contain no active ingredient. They may contain the wrong ingredients or harmful substances. As a result, these products may be ineffective or harmful.
Visible particulate matter was found in at least one falsified batch, STV1K01. This signals a risk of contamination. Patients could face adverse reactions, including infections or injection-related complications.
Patients receiving falsified DARZALEX may not get appropriate treatment for their condition. This can lead to disease progression. It can also increase morbidity and mortality. Prompt detection and removal of these products from the supply chain is essential to prevent patient harm.
Advice to health-care professionals, regulatory authorities, and the public
Health-care professionals should report any unusual adverse events, unexpected lack of therapeutic effects, or observed quality defects associated with DARZALEX to their National Regulatory Authority, National Pharmacovigilance Centre, or WHO at the email below.
WHO advises increased surveillance and monitoring of the supply chain in countries and regions likely to be affected by these falsified products. Increased surveillance of the informal/unregulated market, including online platforms, is especially advised. National regulatory authorities, health authorities, and law enforcement should notify WHO immediately if these products are detected.
If you have these products, do not use them. If you, or someone you know, has, or may have used these products, or suffered an adverse event or unexpected side-effect after use, seek immediate medical advice from a health-care professional. All medical products must be obtained from authorized/licensed suppliers. If you have any information about the manufacture or supply of these products, please contact WHO at [email protected].
Annex: Products subject to the WHO Medical Product Alert N°3/2026
来源：WHO 医疗产品质量警报 · who.int